Equities Analysts Issue Forecasts for Lexeo Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:LXEO)

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Equities researchers at Chardan Capital issued their FY2025 EPS estimates for Lexeo Therapeutics in a research report issued to clients and investors on Wednesday, August 14th. Chardan Capital analyst G. Livshits anticipates that the company will post earnings per share of ($2.46) for the year. Chardan Capital currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($2.65) per share.

Several other analysts have also recently weighed in on LXEO. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. HC Wainwright dropped their target price on shares of Lexeo Therapeutics from $22.00 to $21.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. Baird R W raised shares of Lexeo Therapeutics to a “strong-buy” rating in a report on Thursday, June 13th. Finally, Robert W. Baird assumed coverage on shares of Lexeo Therapeutics in a report on Thursday, June 13th. They set an “outperform” rating and a $28.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $22.14.

Lexeo Therapeutics Price Performance

NASDAQ:LXEO opened at $12.21 on Friday. Lexeo Therapeutics has a 52-week low of $9.00 and a 52-week high of $22.33. The stock has a fifty day moving average of $14.19 and a 200 day moving average of $14.52. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.16 and a current ratio of 9.16. The firm has a market capitalization of $402.26 million and a price-to-earnings ratio of -0.55.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.64) EPS for the quarter, meeting the consensus estimate of ($0.64).

Insiders Place Their Bets

In other news, CEO Richard Nolan Townsend sold 5,000 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $11.53, for a total value of $57,650.00. Following the completion of the sale, the chief executive officer now owns 120,695 shares of the company’s stock, valued at approximately $1,391,613.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.50% of the company’s stock.

Institutional Investors Weigh In On Lexeo Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC increased its stake in Lexeo Therapeutics by 9.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock worth $39,802,000 after purchasing an additional 210,047 shares during the period. Blackstone Inc. purchased a new position in shares of Lexeo Therapeutics in the fourth quarter worth $9,342,000. BNP Paribas Financial Markets bought a new stake in Lexeo Therapeutics during the 1st quarter valued at $75,000. American International Group Inc. bought a new stake in Lexeo Therapeutics during the 1st quarter valued at $79,000. Finally, Omega Fund Management LLC purchased a new stake in Lexeo Therapeutics during the 4th quarter valued at $28,955,000. Institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.